Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends …
Y Zhou, J Wang, Z Gu, S Wang, W Zhu… - Chemical …, 2016 - ACS Publications
Fluoroorganic chemistry has become essential in the evolution of many different but
interconnected research fields. These include the development of new materials with a …
interconnected research fields. These include the development of new materials with a …
Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders
X Yang, B Su, X Zhang, Y Liu, H Wu… - Journal of leukocyte …, 2020 - academic.oup.com
The morbidity and mortality of HIV type-1 (HIV-1)-related diseases were dramatically
diminished by the grounds of the introduction of potent antiretroviral therapy, which induces …
diminished by the grounds of the introduction of potent antiretroviral therapy, which induces …
Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection
SL Walmsley, A Antela, N Clumeck… - … England Journal of …, 2013 - Mass Medical Soc
Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …
recently approved in the United States for the treatment of human immunodeficiency virus …
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING …
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
HIV-1 integrase inhibitors: a comparative review of efficacy and safety
KK Scarsi, JP Havens, AT Podany, SN Avedissian… - Drugs, 2020 - Springer
The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human …
Background Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor
(NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most …
(NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most …
HIV-1 antiretroviral resistance: scientific principles and clinical applications
MW Tang, RW Shafer - Drugs, 2012 - Springer
The efficacy of an antiretroviral (ARV) treatment regimen depends on the activity of the
regimen's individual ARV drugs and the number of HIV-1 mutations required for the …
regimen's individual ARV drugs and the number of HIV-1 mutations required for the …
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel
MA Thompson, JA Aberg, P Cahn, JSG Montaner… - Jama, 2010 - jamanetwork.com
Context Recent data regarding the consequences of untreated human immunodeficiency
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and …
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a …
PE Sax, E DeJesus, A Mills, A Zolopa, C Cohen… - The Lancet, 2012 - thelancet.com
Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the
CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate …
CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate …
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Background New antiretroviral therapy (ART) regimens for HIV could improve clinical
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …